113 related articles for article (PubMed ID: 36858579)
1. The Effect of Iontophoretic-Delivered Polyplex Vaccine on Melanoma Regression.
Husseini RA; Fukuta T; Ozono M; Hasan AA; Megrab NAE; Kogure K
Biol Pharm Bull; 2023; 46(3):494-504. PubMed ID: 36858579
[TBL] [Abstract][Full Text] [Related]
2. Use of Iontophoresis Technology for Transdermal Delivery of a Minimal mRNA Vaccine as a Potential Melanoma Therapeutic.
Husseini RA; Abe N; Hara T; Abe H; Kogure K
Biol Pharm Bull; 2023; 46(2):301-308. PubMed ID: 36724958
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
4. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
5. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
6. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Molino NM; Neek M; Tucker JA; Nelson EL; Wang SW
Biomaterials; 2016 Apr; 86():83-91. PubMed ID: 26894870
[TBL] [Abstract][Full Text] [Related]
7. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.
Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L
J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer vaccination by transdermal delivery of antigen peptide-loaded nanogels via iontophoresis.
Toyoda M; Hama S; Ikeda Y; Nagasaki Y; Kogure K
Int J Pharm; 2015 Apr; 483(1-2):110-4. PubMed ID: 25681719
[TBL] [Abstract][Full Text] [Related]
11. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
12. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
13. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
[TBL] [Abstract][Full Text] [Related]
15. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser DE; Liénard D; Rufer N; Rubio-Godoy V; Rimoldi D; Lejeune F; Krieg AM; Cerottini JC; Romero P
J Clin Invest; 2005 Mar; 115(3):739-46. PubMed ID: 15696196
[TBL] [Abstract][Full Text] [Related]
16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
17. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.
Carreno BM; Becker-Hapak M; Huang A; Chan M; Alyasiry A; Lie WR; Aft RL; Cornelius LA; Trinkaus KM; Linette GP
J Clin Invest; 2013 Aug; 123(8):3383-94. PubMed ID: 23867552
[TBL] [Abstract][Full Text] [Related]
18. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer.
Zupančič E; Curato C; Kim JS; Yeini E; Porat Z; Viana AS; Globerson-Levin A; Waks T; Eshhar Z; Moreira JN; Satchi-Fainaro R; Eisenbach L; Jung S; Florindo HF
Nanomedicine; 2018 Apr; 14(3):835-847. PubMed ID: 29306001
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
Clancy-Thompson E; King LK; Nunnley LD; Mullins IM; Slingluff CL; Mullins DW
Cancer Immunol Res; 2013 Nov; 1(5):332-9. PubMed ID: 24377099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
